There is one clinical trial.
To evaluate the incidence of patients with a positive test for SARS-CoV-2, performed in the preoperative screening for patients treated at the institution
Description: Describe the incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program in our centerMeasure: Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program Time: May- December 2020
Description: Describe the incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test.Measure: Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test; Time: Up to 30 days
Description: Postoperative complications will be recorded, according to the Clavien-Dindo classification.Measure: Postoperative complications Time: Up to 30 days
Description: To evaluate the risk of all-cause mortalityMeasure: Mortality Time: 30 days
Description: Assess the impact of delayed cancer treatmentMeasure: Delay in the cancer treatment Time: May 2020- March 2021
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports